Evidence map›Paper›PMID 26286635›Full record

Trial reportAnnals of nuclear medicine2015

Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT.

Steven P Rowe, Michael A Gorin, Hans J Hammers, M Som Javadi, Hazem Hawasli, Zsolt Szabo, Steve Y Cho, Martin G Pomper, Mohamad E Allaf

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of nuclear medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 5 pooled it
13.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 5 syntheses or guidelines pooled it, 171 citations in OpenAlex.

  1. Pooled it
  2. Utility of PSMA PET/CT in Staging and Restaging of Renal Cell Carcinoma: A Systematic Review and Metaanalysis.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Safety, Biodistribution, and Radiation Dosimetry ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021
    Trial
  7. Prospective Evaluation of PSMA-TargetedJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020
    Trial
  8. Trial
  9. Trial
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Cinematic rendering ofBJUI compass · 2024
    Article
  16. SABR for oligometastatic renal cell carcinoma.Clinical and translational radiation oncology · 2024
    Article
  17. Article
  18. Article
  19. Article
  20. Nuclear medicine and molecular imaging · 2023
    Article

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Steven P RoweThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Michael A GorinThe James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, 600 North Wolfe Street Park 223, Baltimore, MD, 21287, USA.
Hans J HammersThe Department of Medical Oncology at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
M Som JavadiThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Hazem HawasliThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Zsolt SzaboThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Steve Y ChoDepartment of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Martin G PomperThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Mohamad E AllafThe James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, 600 North Wolfe Street Park 223, Baltimore, MD, 21287, USA. mallaf@jhmi.edu.
Johns Hopkins University · USJohns Hopkins Medicine · USUniversity of Wisconsin–Madison · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Theranostic Imaging of Metastatic Prostate CancerP50CA103175 · NCI · JOHNS HOPKINS UNIVERSITY · PI BARKER, PETER B · 2003 to 2015
$17.9M
PSMA-based Cancer Imaging AgentsR01CA134675 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI POMPER, MARTIN G · 2009 to 2025
$6.2M
Training for Clinician Scientists in Imaging ResearchT32EB006351 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI POMPER, MARTIN G · 2006 to 2022
$4.0M
PSMA Directed Imaging of Prostate Cancer Focus on Androgen Receptor DynamicsU01CA183031 · NCI · JOHNS HOPKINS UNIVERSITY · PI DEWEESE, THEODORE L, POMPER, MARTIN G · 2015 to 2017
$1.2M
Social Determinants of Breast Cancer SurvivorshipK01CA184288 · NCI · UNIVERSITY OF PENNSYLVANIA · PI DEAN, LORRAINE TIERA · 2014 to 2018
$767k
NCI NIH HHS CA103175NCI NIH HHS CA134675NCI NIH HHS CA183031NCI NIH HHS CA184288NCI NIH HHS K01 CA184288NCI NIH HHS P30 CA006973NCI NIH HHS P50 CA103175NCI NIH HHS R01 CA134675NCI NIH HHS U01 CA183031NIBIB NIH HHS EB006351NIBIB NIH HHS T32 EB006351
6 · The paper itself

Abstract

objectiveMolecular imaging with positron emission tomography (PET) provides a powerful means of identifying and characterizing cancerous processes, as well as providing a quantitative framework within which response to therapy can be ascertained. Unfortunately, the most commonly used PET radiotracer, ¹⁸F-fluorodeoxyglucose (FDG), has not demonstrated a definitive role in determining response to therapy in metastatic renal cell carcinoma (RCC). As a result, new radiotracers able to reliably image RCC could be of tremendous value for this purpose.

methodsFive patients with known metastatic RCC were imaged with the low-molecular weight radiotracer ¹⁸F-DCFPyL, an inhibitor of the prostate-specific membrane antigen at 60 min post injection. ¹⁸F-DCFPyL PET/CT and conventional images (either contrast-enhanced computed tomography or magnetic resonance imaging) were centrally reviewed for suspected sites of disease.

resultsIn all five patients imaged, sites of putative metastatic disease were readily identifiable by abnormal ¹⁸F-DCFPyL uptake, with overall more lesions detected than on conventional imaging. These PET-detected sites included lymph nodes, pancreatic parenchymal lesions, lung parenchymal lesions, a brain parenchymal lesion, and other soft tissue sites. ¹⁸F-DCFPyL uptake ranged from subtle to intense with maximum standardized uptake values (SUVmax) for the identified lesions of 1.6-19.3. Based upon this small patient series, limited pathology and imaging follow-up of these patients suggests a higher sensitivity for ¹⁸F-DCFPyL compared to conventional imaging in the detection of metastatic RCC (94.7 versus 78.9%).

conclusionsPSMA expression in the tumor neovasculature of RCC has been previously established and is believed to provide the basis for the imaging findings presented here. PSMA-based PET/CT with radiotracers such as ¹⁸F-DCFPyL may allow more accurate staging of patients with RCC and conceivably the ability to predict and follow therapy in patients treated with agents targeting the neovasculature.

Indexed as

Multimodal ImagingPositron-Emission TomographyTomography, X-Ray ComputedAgedAntigens, SurfaceCarcinoma, Renal CellGlutamate Carboxypeptidase IIHumansKidney NeoplasmsLysineMaleMiddle AgedNeoplasm MetastasisUrea2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acidAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IILysineUreaDCFPyLPositron emission tomography (PET)Prostate-specific membrane antigen (PSMA)Renal cell carcinoma (RCC)

Identifiers

PMID26286635
PMCPMC4666821
OpenAlexW1523804735

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.